Becker's Healthcare September 12, 2024
Claire Wallace

The FDA has approved Johnson & Johnson’s Tremfya to treat adults with moderate to severe ulcerative colitis.

It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
A Sea-Change is Coming in How Laboratory-Developed Tests are Regulated – Is your Lab Ready?
The AI assurance labs are coming
The FDA Isn’t Blocking Medical Breakthroughs — Our Outdated Innovation Model Is
GLP-1 weight loss pills are in the works: What to know
FDA and the Fountain of Youth: Regulatory Hurdles in the Longevity Biotech Community

Share This Article